As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Mirum Pharamaceuticals, Inc. The largest reported stake is JANUS HENDERSON GROUP Ltd.'s, at 9.7%. 13 filings are on record since August 14, 2025 (Schedule 13G/A, August 13, 2026).
Sell to companies like Mirum Pharamaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: JANUS HENDERSON GROUP Ltd. · Sole voting: 0 · Shared voting: 5,909,184 · Sole dispositive: 0 · Shared dispositive: 5,909,184 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Fmr LLC · Sole voting: 3,776,727 · Shared voting: 0 · Sole dispositive: 3,777,851 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-06
- · Holder: BlackRock, Inc. · Percent: 5.7% · SCHEDULE 13G/A
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
- · Holder: Janus Henderson Group Plc · Percent: 11.8% · SCHEDULE 13G/A
Mirum Pharamaceuticals, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-14. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 9.7% | 5,909,184 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Frazier Life Sciences IX, L.P. | 6.8% | 3,566,912 | SCHEDULE 13D/A, 2026-01-27 | 2026-01-23 |
| Fmr LLC | 6.2% | 3,777,851 | SCHEDULE 13G, 2026-08-06 | 2026-06-30 |
| BlackRock, Inc. | 5.7% | 3,465,559 | SCHEDULE 13G/A, 2026-04-27 | 2026-03-31 |
| Eventide Asset Management, LLC | 4.1% | 2,093,582 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Bvf Partners L P | 3% | 1,495,290 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Mirum Pharamaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Mirum Pharamaceuticals, Inc. and the records around it.
Mirum Pharamaceuticals, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Form D filing Jan 2026
- Acquisition Jan 2026
- Who owns it
Companies that share a holder
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026), Beta Bionics, Inc. (May 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Watch Mirum Pharamaceuticals, Inc.
Get an email when Mirum Pharamaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mirum Pharamaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mirum Pharamaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mirum Pharamaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 0 | 5,909,184 | 0 | 5,909,184 | SCHEDULE 13G/A, 2026-08-13 |
| Fmr LLC | 3,776,727 | 0 | 3,777,851 | 0 | SCHEDULE 13G, 2026-08-06 |
| Abigail P. Johnson | 0 | 0 | 3,777,851 | 0 | SCHEDULE 13G, 2026-08-06 |
The latest filing identifies Mirum Pharamaceuticals, Inc. by CUSIP 604749101 and gives its principal executive office as 989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA 94404 (SCHEDULE 13G/A, 2026-08-13).
Purpose of Transaction (Item 4)
Frazier Life Sciences IX, L.P.
Item 4 is hereby amended and restated in its entirety to read as follows: Each of FLS IX, FLS X, FLSPF, FLS XI and FLS XII acquired the FLS IX Shares, the FLS X Shares, the FLSPF Shares, the FLS XI Shares and the FLS XII Shares, as the case may be, for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, FLS IX, FLS X, FLSPF, FLS XI and FLS XII and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-27; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Janus Henderson Group Plc | 10.6% | SCHEDULE 13G/A |
| 2025-08-20 | Frazier Life Sciences IX, L.P. | 7.6% | SCHEDULE 13D/A |
| 2025-11-04 | Frazier Life Sciences IX, L.P. | 7.6% | SCHEDULE 13D/A |
| 2025-11-14 | Bvf Partners L P | 3% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 10% | SCHEDULE 13G/A |
| 2025-12-05 | Janus Henderson Group Plc | 10.6% | SCHEDULE 13G/A |
| 2026-01-27 | Frazier Life Sciences IX, L.P. | 6.8% | SCHEDULE 13D/A |
| 2026-02-13 | Eventide Asset Management, LLC | 4.1% | SCHEDULE 13G/A |
| 2026-02-17 | Janus Henderson Group Plc | 11.8% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-27 | BlackRock, Inc. | 5.7% | SCHEDULE 13G/A |
| 2026-08-06 | Fmr LLC | 6.2% | SCHEDULE 13G |
| 2026-08-13 | JANUS HENDERSON GROUP Ltd. | 9.7% | SCHEDULE 13G/A |
Questions about who owns Mirum Pharamaceuticals, Inc.
Who owns Mirum Pharamaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Mirum Pharamaceuticals, Inc.: JANUS HENDERSON GROUP Ltd. (9.7%, Schedule 13G/A, filed 2026-08-13), Frazier Life Sciences IX, L.P. (6.8%, Schedule 13D/A, filed 2026-01-27), Fmr LLC (6.2%, Schedule 13G, filed 2026-08-06) and BlackRock, Inc. (5.7%, Schedule 13G/A, filed 2026-04-27).
Who are the largest shareholders of Mirum Pharamaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Mirum Pharamaceuticals, Inc. on this page are JANUS HENDERSON GROUP Ltd. (9.7%), Frazier Life Sciences IX, L.P. (6.8%) and Fmr LLC (6.2%).
When did JANUS HENDERSON GROUP Ltd. buy into Mirum Pharamaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from JANUS HENDERSON GROUP Ltd. on this page is the Schedule 13G/A, filed 2026-08-13, reporting 9.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Mirum Pharamaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 8, 2026 | Leadership change: Rob Myers appointed, Chief Medical Officer, and 1 more | — | Leadership changes | Source |
| January 29, 2026 | Form D, private offering | $68.48M sold | Form D page | Source |
| January 23, 2026 | Acquired Bluejay Therapeutics, Inc. | $280.80M | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for Mirum Pharamaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.